Could a single dose of a new drug boost depression relief?

NCT ID NCT04937829

Completed Disease control Sponsor: Boehringer Ingelheim Source: ClinicalTrials.gov ↗

First seen Aug 14, 2026 · Last updated Aug 14, 2026

Summary

This trial tests an experimental medicine called BI 1569912 in adults aged 18 to 65 with major depressive disorder whose current antidepressants aren't working well enough. Participants take a single dose of the drug or a placebo, in addition to their usual antidepressant, and are monitored for about five weeks. The study aims to see if the drug is safe, how the body processes it, and whether it may help reduce depression symptoms.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: an experimental drug called BI 1569912, taken as a tablet alongside usual antidepressant medication
What this could lead to: If successful, this could point toward a new add-on treatment for people with major depression who don't get enough relief from standard antidepressants.
What could go wrong: This is an early, small phase 1 study focused on safety and tolerability, so it's too soon to know if the drug truly helps. It may not show meaningful benefit, and side effects are still being evaluated.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DEPRESSIVE DISORDER, MAJOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

major depressive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DEPRESSIVE DISORDER, MAJOR

Contacts and locations

Locations

Collaborative Neuroscience Network, LLC (CNS)

Garden Grove, California, 92845, United States
Collaborative Neuroscience Research, LLC

Torrance, California, 90504, United States
Hassman Research Institute

Berlin, New Jersey, 08009, United States
Hassman Research Institute

Marlton, New Jersey, 08053, United States
InSite Clinical Research

DeSoto, Texas, 75115, United States
Neuro-Behavioral Clinical Research

North Canton, Ohio, 44720, United States
Optimus U Corporation

Miami, Florida, 33135, United States
Pillar Clinical Research, LLC

Richardson, Texas, 75080, United States
Research Centers of America

Oakland Park, Florida, 33334, United States
iResearch Atlanta

Decatur, Georgia, 30030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.